Comparative study of immune potency of two different trivalent FMD vaccines in cattle

摘要

Foot and mouth disease (FMD) is highly infectious disease of cloven hoofed animals. It causes an acute disease characterized by fever, lameness and vesicular lesion on the feet, tongue, snout and teats, with high morbidity and low mortality (El-Moety et al. 2013). Although vaccines, available since the early 1900s, have been instrumental in eradicating FMD from parts of the world, the disease still affects millions of animals around the globe and remains the main sanitary barrier to the commerce of animals and animal products. This study was planned to record the immune response by compliment fixation test in cattle vaccinated with trivalent inactivated aluminum hydroxide gel (AL (OH)3) and oil adjuvant vaccine (Montanide ISA206). Twenty cattle were included in the study and were classified into four groups: 1st group was vaccinated with (company-1) vaccine as priming dose and after 30 days booster was given to the same group with oil based vaccine through subcutaneous and intramuscular route respectively; 2nd group was vaccinated with (company-1) vaccine both for priming as well as for boosting after 30-days with intramuscular route; 3rd group vaccinated with double oil emulsion inactivated vaccine (company-2) through intramuscular route for both priming and boosting was done after 30-days of priming and 4th group was vaccinated with double oil emulsion inactivated vaccine (company-2) as priming with boosting after 30 days by subcutaneous route. 5th group (5-animals) was non-vaccinated and kept as a control group. The data revealed non-significant difference (p>0.05) among the four different groups administered with FMDV vaccines when evaluated at day 30 post vaccination significant difference (p<0.05) was seen at day 60 and 90 post vaccination. Group 1, 2, 3 and 4 showed CGMT±SD values of 15.3067±1.20089, 8.7867±0.68127, 12.1967±1.68631 and 3.22±0.70449 respectively. Analysis of variance showed significant difference (p<0.05) in antibodies level between groups and with in groups at day 60 and 90 post vaccination. On the 60th antibodies in group 1 where Company-1 vaccine was used, gave highest mean values followed by group 3 (Company-2 vaccine). Group 2 revealed lower followed by group 4 that showed lowest mean values of antibodies. Antibody titer of group 2 at day 90 same pattern as observed above for other group. It was concluded that the selection of proper adjuvant with priming and boosting combination are the factors affecting the potency of FMDV vaccines rather than the antigen serotypes FMDV vaccine components.